Clinical Trial News
Merck's Keytruda has done it again.
The safety profile of Cosentyx was in line with the known safety profile.
Top-line results from this study are expected in the second half of 2019.
CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a synthetic, ultra-pure injection of trans-capsaicin designed to be injected directly into the painful joint to provide rapid and durable pain relief.
The Oraxol Phase III clinical study is a randomized controlled international clinical trial investigating the superiority of Oraxol over intravenous paclitaxel in the treatment of patients with metastatic breast cancer.
Gamida Cell today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma.
Additionally, the company announced the first patient has been dosed in the Phase 1 trial of AVXS-101 in SMA Type 2.
The trial will comprise a total of 60 volunteers. Saniona expects to report results from the trial in the second quarter 2018.
The TRX518-003 study is a multipart study evaluating TRX518 as a monotherapy and in combination with gemcitabine, KEYTRUDA, or Opdivo in patients with advanced solid tumor malignancies.